Immunomic Discovery of Adjuvants, Delivery Systems, and Candidate Subunit Vaccines: A Brief Introduction

  • Darren R. FlowerEmail author
  • Yvonne Perrie
Part of the Immunomics Reviews: book series (IMMUN, volume 5)


Mass vaccination, when coupled to profound improvements in general sanitation, has given rise to the most remarkable transformation in public health in human history. Yet the development of vaccines remains largely trapped in the past, a hostage to the methodology of Pasteur. Infectious disease continues to threaten humanity, with new and renascent diseases emerging continually. The last two decades have seen a breath-taking revival in the commercial market for vaccines and the simultaneous emergence of a whole tranche of new technologies that promise to free vaccine development from the muddle of empirical thinking. In this short introduction, we set the scene for this renaissance, and explore how the combination of computational and experimental techniques promise so much for the future development of vaccines and the science of vaccinology.


Vaccine Delivery Francisella Tularensis Diphtheria Toxoid Cannabis Abuse Particulate Delivery System 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Murray CJ, Rosenfeld LC, Lim SS, Andrews KG, Foreman KJ, Haring D, Fullman N, Naghavi M, Lozano R, Lopez AD (2012) Global malaria mortality between 1980 and 2010: a systematic analysis. Lancet 379:413–431PubMedCrossRefGoogle Scholar
  2. 2.
    Berkowitz B, Spector S (1972) Evidence for active immunity to morphine in mice. Science 178:1290–1292PubMedCrossRefGoogle Scholar
  3. 3.
    Bonese KF, Wainer BH, Fitch FW, Rothberg RM, Schuster CR (1974) Changes in heroin self-administration by a rhesus monkey after morphine immunisation. Nature 252:708–710PubMedCrossRefGoogle Scholar
  4. 4.
    World Health Organization. Manual for the production and control of vaccines—tetanus toxoid. blg/undp/77.2 Rev.1, 1977 [ref type: serial (book, monograph)].Google Scholar
  5. 5.
    Allison AG, Gregoriadis G (1974) Liposomes as immunological adjuvants. Nature 252:252PubMedCrossRefGoogle Scholar
  6. 6.
    Henriksen-Lacey M, Bramwell VW, Christensen D, Agger E-M, Andersen P, Perrie Y (2010) Liposomes based on dimethyldioctadecylammonium promote a depot effect and enhance immunogenicity of soluble antigen. J Control Release 142(2):180–186PubMedCrossRefGoogle Scholar
  7. 7.
    Kamath AT, Rochat A-F, Christensen D, Agger EM, Andersen P, Lambert P-H, Siegrist C-A (2009) A liposome-based mycobacterial vaccine induces potent adult and neonatal multifunctional T cells through the exquisite targeting of dendritic cells. PLoS One 4:e5771PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.School of Life and Health SciencesUniversity of AstonBirminghamUK
  2. 2.School of Life and Health SciencesUniversity of AstonBirminghamUK

Personalised recommendations